2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
June 6th, 2025
Version: 1
Osteoneurogen
cancer biology
biorxiv

Sequential Activation of Senescence and Apoptosis by ONG41008 Eliminated the Human Pancreatic Ductile Adenocarcinoma in nude mice and xenografted human lung cancer

Youn, B.-S.Open in Google Scholar•Kim, K.Open in Google Scholar•Kim, Y.Open in Google Scholar

Current therapeutic limitations associated with pancreatic ductal adenocarcinoma (PDAC) are still evident. We have found that ONG41008, the first human synthetic polyphenol, is able to eradicate PDAC in a nude mouse model. ONG41008 is known to potently attenuate human TGF-{beta} production, inducing both anti-fibrotic capacity and anticancer potential through senescence-coupled apoptosis (SCA). These interesting observations closely paralleled ONG41008\'s ability to inhibit PDACs, and as expected, ONG41008 alone was able to actually ablate engrafted PDACs in nude mice. Interestingly, the anti-PD 1 developed by MSD did not appear to act on immune activation of exhausted Cd8+ T cells in the tumor microenvironment (TME), but primarily on engrafted PDAC blood vessels. These observations support the latest report from MSD. A549 cells known to be a well appreciated human lung adenocarcinoma cell line were treated with ONG41008. Consistent with the prior observations ONG41008 notably induced SCA. and when A549 cells were xenografted into mice daunting tumor formations were noticed. Upon stimulation with ONG41008 via direct intramural injection of these tumors\' tumor volumes were rapidly regressed. Taken together, we believe that ONG41008 could be a multifaceted anti-cancer agent not only against PDAC but also against other aggressive cancers such as lung cancer.

Similar Papers

biorxiv
Sat Jun 07 2025
Targeting Neutrophil Extracellular Traps to inhibit Colon Cancer Tumor Necrosis and Metastasis
Necrosis, conventionally thought of as a passive consequence of aggressive tumor growth, is associated with poor prognosis in colorectal cancer (CRC). We recently discovered that necrosis can be caused by neutrophil extracellular trap (NET) aggregates driving vascular occlusion within the tumor vasculature in models of breast cancer. Here, we evaluated the role of NETs in inducing necrosis and met...
Gazzara, E.
•
Adrover, J. M.
•
Lui, A.
•
Han, S.
...•
Gholami, S.
biorxiv
Fri Jun 06 2025
Statin-dye conjugates for selective targeting of KRAS mutant cancer cells
Over 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve KRAS mutations (KRASMUT), for which current treatment options are limited. Statins, commonly used to lower cholesterol, have demonstrated certain selective toxicity towards KRAS-transformed cells, prompting the question of whether statins could achieve selective uptake specifically in KRASMUT cells. To investigate this, we synthe...
Moon, H.-r.
•
Cai, Z.
•
Cho, B. K.
•
Chang, H.
...•
Ryu, J. H.
biorxiv
Fri Jun 06 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival
Cancer progression involves loss of differentiation and acquisition of stem cell-like traits, broadly referred to as "stemness". Here, we test whether the level of stemness, assessed by a transcriptome-derived Stemness score, can quantitatively track prostate cancer (PCa) development, progression, therapy resistance, metastasis, plasticity, and patient survival. Integrative analysis of transcripto...
Liu, X.
•
Cortes, E.
•
Ji, Y.
•
Zhao, K.
...•
Tang, D. G.
biorxiv
Fri Jun 06 2025
BEHAV3D Tumor Profiler to map heterogeneous cancer cell behavior in the tumor microenvironment
Intravital microscopy (IVM) enables live imaging of animals at single-cell level, offering essential insights into cancer progression. This technique allows for the observation of single-cell behaviors within their natural 3D tissue environments, shedding light on how genetic and microenvironmental changes influence the complex dynamics of tumors. IVM generates highly complex datasets that often e...
Rios-Jimenez, E.
•
Zomer, A.
•
Collot, R.
•
Barrera Roman, M.
...•
Alieva, M.
biorxiv
Fri Jun 06 2025
Astrocyte reprogramming drives tumor progression and chemotherapy resistance in agent-based models of breast cancer brain metastases
Breast cancer brain metastases (BCBM) affect nearly 90,000 patients annually in the United States and carry a significant risk of mortality. As metastatic lesions develop, the unique milieu of the brain microenvironment shapes disease progression and therapeutic response. Among resident brain cells, astrocytes are both the most common, and are increasingly recognized as key regulators of this proc...
Kaur, R.
•
Barker-Clarke, R.
•
Dhawan, A.
biorxiv
Fri Jun 06 2025
Modelling medulloblastoma pathogenesis and treatment in human cerebellar organoids.
Faithful genetically engineered in vivo models of medulloblastoma (MB) are currently available only for some molecular subgroups, in keeping with recent studies showing the unique role of human-specific progenitors in the development of G3 and G4 MB subgroups. We generated human cerebellar organoids (CbO) from expanded potential stem cells (EPSC) and characterised their epigenetic and transcriptom...
Willott, T. O.
•
Nicholson, J. G.
•
Xiao, Y.
•
Ogunbiyi, O. K.
...•
Marino, S.
biorxiv
Fri Jun 06 2025
Lactate cannot replace glucose for maintaining the viability of mouse and human glioma cells
Objectives: Aerobic lactic acid fermentation (the \'\'Warburg effect\'\') is associated with OxPhos insufficiency and altered energy metabolism in most cancers. Whether lactate is a major fuel in cancer cells remains debated. This study investigated whether lactate could serve as a metabolic fuel in glioma cells and replace glucose to support viability. Methods: A bioluminescence ATP assay and cal...
Miller, E. Y.
•
Duraj, T.
•
Ta, N. L.
•
Lee, D. C.
...•
Seyfried, T. N.
biorxiv
Thu Jun 05 2025
Contrastive Learning-Enhanced Drug Metabolite Prediction Drives the Discovery of an Orally Bioavailable RSK4 Inhibitor for Esophageal Cancer
Drug metabolism liabilities are a major bottleneck in drug development, necessitating accurate metabolite prediction tools. While AI-driven methods have advanced, challenges remain in achieving high-precision, robustness, broad reaction coverage and seamless integration into the drug development workflow. To address this, we first constructed the most comprehensive human-specific drug metabolism d...
He, H.
•
Zhang, M.
•
Yang, X.
•
He, S.
...•
Li, S.
biorxiv
Thu Jun 05 2025
Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer
Autophagy inhibitors are promising compounds to treat pancreatic ductal adenocarcinoma (PDA) but their efficacy in patients is unclear, highlighting a need to understand mechanisms of resistance. We used a novel approach to uncover metabolic adaptations that bypass autophagy inhibition. Utilizing PDA cells with acquired resistance to different autophagy inhibitors, we found that severe autophagy d...
Dufresne, S.
•
Kuna, R. S.
•
Wong, K.
•
Komarla, A.
...•
Towers, C. G.